Neuronet - Efficiently Networking European Neurodegeneration Research

          Press Release - May 9, 2022

The Neuronet releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies

Madrid, 9 May 2022 – Today, the members of the Neuronet (Efficiently Networking European Neurodegeneration Research) programme are pleased to announce the launch of an updated version of their Decision Tool to support engagement with Regulatory and Health Technology Assessment (HTA) bodies. The Decision Tool now provides a clickable overview of the processes and procedures for HTA and regulatory interactions at different stages of the development pipeline. This will help ensure that the outputs being developed by projects are relevant for regulatory and HTA settings, where applicable.

Neuronet is a Coordination and Support Action aiming to support and better integrate projects of the Innovative Medicines Initiative’s (IMI) neurodegeneration (ND) research portfolio. One of Neuronet’s workstreams aims to develop tools and services to support IMI ND projects in areas where unmet needs have been identified, which include the need for further support for interactions with HTA and regulatory agencies.

Representatives of the Neuronet project partner, NICE (UK National Institute for Health and Care Excellence) have performed a general update of the Decision Tool that is going live on 9 May. This involved updating the signposting information and text to include any changes to organisations and processes and providing case studies from projects within the Neuronet portfolio that have been through HTA or regulatory processes and procedures. Additional signposting information on relevant agencies, organisations, tools and projects was also incorporated.

Access the Decision Tool


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

Any related content solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

          Press Release - May, 9, 2022

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
NEURONET project · 14, rue Dicks · Luxembourg 1417 · Luxembourg

Email Marketing Powered by Mailchimp